Fajardo TYL, Nápoles MJD, Álvarez AA

Language: Spanish
References: 10
Page: 1-9
PDF size: 279.56 Kb.

ABSTRACT

Introduction: The use of a predictive evaluation system for maternal risk in preeclampsia called FullPIERS test (Preeclampsia Integrated Estimate of Risk) was introduced into the Cuban protocol for hypertension and pregnancy in 2017. Variables such as gestational age, dyspnea / chest pain, creatinine, platelets, glutamic oxaloacetic transaminase and oxygen saturation are used for its calculation.
Objective: To determine the predictive value of postpartum chronic arterial hypertension of FullPIERS test in patients with history of pre-eclampsia.
Methods: A prospective cohort study was carried out in the maternity ward at Carlos Manuel de Céspedes University Hospital in Bayamo, Granma, Cuba, from March 1, 2017 to February 29, 2020. One hundred sixty-two patients with preeclampsia were studied.
Results: The age range between 20 and 35 years predominated with a mean of 26.8 years. In the univariate analysis, elevated creatinine above 70.72 μmmol/L has a RR of (3.088); the FullPIERS test greater than 5% a RR of (2,002), TGP greater than 49 IU a RR (2,112) and the platelet count was less than 150 thousand a RR of (1,550). In multivariate analysis, only creatinine increased above 70.72 μmmol/L constitutes a predictor factor.
Conclusions: FullPIERS test has no predictive value in postpartum chronic arterial hypertension.

REFERENCES

1. Von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83–102. DOI: http://doi.org/10.1016/j.bpobgyn.2016.05.005.

2. Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gyneco. 2012;206(6):470-5. DOI: http://doi.org/c3ft89.

3. American College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstetrics & Gynecology. 2013; 122(5):1122–31. DOI: http://doi.org/10.1097/01.aog.0000437382.03963.88.

4. Protocolo para el manejo de la hipertensión en el embarazo en Cuba. PAMI nacional. Febrero 2017.

5. Pels A, von Dadelszen P, Engelbrecht S, Ryan H, Bellad M, Lalonde A, Magee LA. Timing and mode of delivery. In: Magee L, von Dadelszen P, Stones W, Mathai M, editors. In: The FIGO Textbook of Pregnancy Hypertension an Evidence-Based Guide to Monitoring, Prevention and Management. London, UK: The Global Library of Women’s Medicine (GLOWM); 2016. pp. 167–83. [Google Scholar]

6. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000 Jan 15;19(1):113-32. | PubMed |

7. Baneshi MR, Talei AR. Dichotomization of Continuous Data: Review of Methods, Advantages, and Disadvantages. Iran J Cancer Prev. 2011;l4(1):26-32.

8. Von Dadelszen P, Menzies JM, Payne B, Magee LA PIERS (Preeclampsia Integrated Estimate of RiSk) Study Group. Predicting adverse outcomes in women with severe pre-eclampsia. Semin Perinatol. 2009;33:152–7. DOI: http://doi.org/10.1053/j.semperi.2009.02.009.

9. Payne BA, Hutcheon JA, Ansermino JM. MiniPIERS Study Working Group. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) multi-country prospective cohort study. PLoS Med. 2014;11:e1001589. DOI: http://doi.org/10.1371/journal.pmed.1001589. [PMC free article]

10. Akkermans J, Payne B, von Dadelszen P, Groen H, Vries JD, Magee LA, et al. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58–62. DOI: http://doi.org/10.1016/j.ejogrb.2014.05.021.